NASDAQ$BEAM
Beam Therapeutics Inc. · Q1 2020 earnings
Q1 2020 earnings · · Investor relations
Briefing
Beam Therapeutics reported its first quarter 2020 financial results and presented additional data at the ASGCT Annual Meeting.
Beam Therapeutics reported its Q1 2020 financial results, highlighting a net loss of $31.7 million, or $1.03 per share, and a cash position of $253.4 million. The company also presented promising data from its base editing programs at the ASGCT Annual Meeting, including in vivo proof of concept for alpha-1 antitrypsin deficiency and potential best-in-class approaches for sickle cell disease.
- Presented in vivo proof of concept for base editing in alpha-1 antitrypsin deficiency.
- Showcased two potentially best-in-class approaches for base editing in sickle cell disease.
- Observed more than 90% editing and a more than 65% increase in gamma globin levels in HPFH program.
- Cash, cash equivalents and marketable securities were $253.4 million as of March 31, 2020.
Headline financials
Revenue & EPS history
Beam Therapeutics · Revenue · Quarterly
$6K
Revenue by segment
Beam Therapeutics · $6K total across 1 segment · Q2 2021
- License & collaboration revenue$6K—100.0%
Forward guidance
Beam Therapeutics continues to execute its business objectives for 2020, while closely monitoring the impact of the evolving COVID-19 pandemic and advancing critical research and development activities to support an initial wave of Investigational New Drug (IND) applications beginning in 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2020
+1.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
+3.6%
Avg return
30 days after
56%
14 / 25 earnings
Positive
+21.8%
Q4 2023
Best reaction
-11.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.8% | -2.4% | -9.3% | |
| Q4 2025 | +14.1% | +0.5% | -16.6% | |
| Q3 2025 | -6.4% | -8.4% | +19.2% | |
| Q1 2025 | +3.9% | -0.2% | -1.1% | |
| Q4 2024 | -3.1% | -14.5% | -27.9% | |
| Q3 2024 | +9.3% | +11.1% | +3.9% | |
| Q2 2024 | -4.5% | -4.5% | -5.6% | |
| Q1 2024 | -2.4% | -6.7% | +5.7% | |
| Q4 2023 | +21.8% | +11.3% | -7.7% | |
| Q3 2023 | -11.1% | -12.2% | +5.6% | |
| Q2 2023 | +2.2% | +0.0% | -1.5% | |
| Q1 2023 | +1.9% | +4.3% | -6.7% | |
| Q4 2022 | -1.3% | +0.3% | -22.7% | |
| Q3 2022 | -10.3% | +19.0% | +3.0% | |
| Q2 2022 | +3.2% | +8.5% | -10.4% | |
| Q1 2022 | +0.3% | -0.6% | +12.6% | |
| Q4 2021 | -1.7% | -14.3% | -20.5% | |
| Q3 2021 | +9.1% | +2.9% | -11.4% | |
| Q2 2021 | +1.0% | -5.6% | +1.0% | |
| Q1 2021 | +4.3% | +12.2% | +37.1% | |
| Q4 2020 | -4.4% | -5.6% | -22.3% | |
| Q3 2020 | +2.5% | -1.4% | +109.9% | |
| Q2 2020 | -5.1% | -3.5% | +8.6% | |
| Q1 2020 | +3.3% | +3.4% | +23.1% | |
| Q4 2019 | +3.3% | +3.4% | +23.1% | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro